Gland Pharma launches cancer drug Bortezomib in US
Advertisement
Hyderabad: Gland Pharma Limited, a generic injectable focused pharmaceutical company, through its partner has launched Bortezomib for Injection, 3.5 mg/vial, Single-Dose Vial in the US Market.
It is the bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Velcade for Injection, 3.5 mg/vial of Takeda Pharmaceuticals U.S.A., Inc.
Bortezomib for Injection is used to treat certain types of cancer such as multiple myeloma (cancer of plasma cells) and mantle cell lymphoma (cancer of lymph nodes).
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.